Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells

Abstract

SummaryThe search for immunostimulatory drugs applicable to cancer immunotherapy may profit from target‐agnostic methods in which agents are screened for their functional impact on immune cells cultured in vitro without any preconceived idea on their mode of action. We have built a synthetic mini‐immune system in which stressed and dying cancer cells (derived from standardized cell lines) are confronted with dendritic cells (DCs, derived from immortalized precursors) and CD8+ T‐cell hybridoma cells expressing a defined T‐cell receptor. Using this system, we can identify three types of immunostimulatory drugs: (i) pharmacological agents that stimulate immunogenic cell death (ICD) of malignant cells; (ii) drugs that act on DCs to enhance their response to ICD; and (iii) drugs that act on T cells to increase their effector function. Here, we focus on strategies to develop drugs that enhance the perception of ICD by DCs and to which we refer as “ICD enhancers.” We discuss examples of ICD enhancers, including ligands of pattern recognition receptors (exemplified by TLR3 ligands that correct the deficient function of DCs lacking FPR1) and immunometabolic modifiers (exemplified by hexokinase‐2 inhibitors), as well as methods for target deconvolution applicable to the mechanistic characterization of ICD enhancers.